We monitor the scientists, clinical trials, and biotech programs working toward a durable cure. We verify the evidence, explain what it actually means, and tell you what's still unproven — in plain English, with the denominators included.
Endogenous insulin production, or a biological replacement sufficient for control — not "reduced use."
Reliable control that lasts — not a short-lived signal or an isolated lab result.
Safety and quality of life are part of the finish line, not an asterisk on it.
A band (how it ranks) and an evidence tier (how proven it is) — always shown together, never a rank alone. Full methodology and the complete tracked-programs list here.
One patient, zero immunosuppression, insulin production still detectable past 14 months. First human proof the hardest unsolved piece — immune evasion — can work at all.
Full Trial Report Card →10 of 12 full-dose participants insulin-independent at one year. The strongest human efficacy evidence tracked so far — still requires standard immunosuppression.
Full Trial Report Card →No human trial yet — designed to solve both unsolved problems, cell replacement and immune evasion, at once. IND targeted Q4 2026.
Full Trial Report Card →12 of 12 donor-islet recipients insulin-independent in a UChicago Medicine pilot. Small and uncontrolled, but a real near-term benefit for people on transplant waitlists today.
Full Trial Report Card →Every claim is checked against ClinicalTrials.gov, FDA filings, peer-reviewed journals, and company investor communications — in that order of trust — before it reaches a caption.
"Insulin independence" and "cure" are not the same claim. We separate management, disease modification, functional cure, and durable cure — every time.
When a program's status changes, we say what we originally said, what changed, and why — labeled, not buried.